The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies.

Written by Julia Kollewe for The Guardian. GlaxoSmithKline has been pulling cash out of some eurozone countries in case the debt crisis takes a turn for the worse. Speaking at the drugmaker’s annual results presentation in London, the recently knighted chief executive Sir Andrew Witty said in the past year the company had been withdrawing more »

Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer.

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Takeda Pharmaceuticals is a top pharmaceutical company based in Osaka, Japan

Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada

With 85 deals announced, the first quarter of 2014 started strongly for life science M&A

Sanofi is a top pharmaceutical company based in Paris, France

Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India

UCB is a top pharmaceutical company based in Brussels, Belgium

Written by Julia Kollewe for The Guardian. GlaxoSmithKline has been pulling cash out of some eurozone countries in case the debt crisis takes a turn for the worse. Speaking at the drugmaker’s annual results presentation in London, the recently knighted chief executive Sir Andrew Witty said in the past year the company had been withdrawing more »

Teva and Auspex Pharmaceuticals have entered into a definitive merger agreement

Minerva Neurosciences will raise approximately $31 million of gross proceeds in a private placement offering to several institutional investors

Concordia Healthcare has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis Pharma and Covis Injectables for US$1.2 billion

Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging

REGENXBIO announced the completion of a $30 million Series C financing

DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.

Shire and ArmaGen announced a worldwide pharma licensing and collaboration agreement for AGT-182.

Bionomics has entered into an exclusive research collaboration and pharma licensing Agreement with Merck for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions.

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing.